Vyvanse and Zenpep drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vyvanse (lisdexamfetamine dimesylate) and Zenpep (pancrelipase (amylase;lipase;protease)). Common drug interactions include blindness among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Vyvanse and Zenpep. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,870 Vyvanse users. Check the latest studies of Vyvanse.

What is Zenpep?

Zenpep has active ingredients of pancrelipase (amylase;lipase;protease). eHealthMe is studying from 5,529 Zenpep users. Check the latest studies of Zenpep.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

25 people who take Vyvanse and Zenpep together, and have interactions are studied.

What are the common drug interactions of Vyvanse and Zenpep, by gender? *:

female:

Blindness
Joint swelling
Rhinorrhoea (watery mucus discharge from the nose)
Chest discomfort
Dyspnoea (difficult or laboured respiration)

male:

Anxiety
Blood sodium decreased
Somnolence (a state of near-sleep, a strong desire for sleep)
Stress
Bacterial infection
Blood alkaline phosphatase increased
Blood glucose decreased
Blood pressure systolic increased
Burning sensation
Cystic fibrosis related diabetes

What are the common drug interactions of Vyvanse and Zenpep, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Sinus disorder (disease of sinus)
Drug hypersensitivity
Respiratory tract infection
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Rhinorrhoea (watery mucus discharge from the nose)

20-29:

n/a

30-39:

Blood alkaline phosphatase increased
Burning sensation
Irritability
Joint injury
Limb injury
Road traffic accident

40-49:

Blindness
Joint swelling

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 12 people, 48.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 10 people, 40.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 8.00%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Vyvanse and Zenpep?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously